SCHEMBL3607358

SCHEMBL3607358

CCOC(=O)c1[nH]c2ccc(Br)cc2c1S(=O)(=O)NCCOC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 6/20 0.45
KDM4E B2RXH2 7/20 0.44
HIF1A Q16665 2/20 0.44
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44
TUBB6 Q9BUF5 1/20 0.44
TUBB2B Q9BVA1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605244 0.79 ALDH1A1 (0.49) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2346386 0.77 GAA (0.51) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL3609667 0.76 BRAF (0.47) MEN1KMT2AMAPTKDM4EHIF1A
SCHEMBL7556498 0.76 ALDH1A1 (0.54) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL4920737 0.76 TUBB4A (0.49) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL333983 0.75 ALDH1A1 (0.53) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2876735 0.75 LMNA (0.56) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL3011731 0.75 ALDH1A1 (0.69) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL2348114 0.74 HIF1A (0.44) LMNAMEN1KMT2AMAPTKDM4E
SCHEMBL3602053 0.74 LMNA (0.58) LMNAMEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222322-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK & CO., INC. (US) 2010-09-02 US claimed
EP-1899340-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 EP claimed
WO-2007002368-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 WO claimed
US-20100222322-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK & CO., INC. (US) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222322-A1 Non-Nucleoside Reverse Transcriptase Inhibitors IDO1, IDO2, INMT LMNA 3908/4885MEN1 4344/4885KMT2A 1067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.